+

WO2000076490A3 - Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin - Google Patents

Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin Download PDF

Info

Publication number
WO2000076490A3
WO2000076490A3 PCT/US2000/040183 US0040183W WO0076490A3 WO 2000076490 A3 WO2000076490 A3 WO 2000076490A3 US 0040183 W US0040183 W US 0040183W WO 0076490 A3 WO0076490 A3 WO 0076490A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxybutynin
urgency
treating urinary
compositions
urinary frequency
Prior art date
Application number
PCT/US2000/040183
Other languages
French (fr)
Other versions
WO2000076490A2 (en
Inventor
Paul D Rubin
Original Assignee
Sepracor Inc
Paul D Rubin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc, Paul D Rubin filed Critical Sepracor Inc
Priority to AU64036/00A priority Critical patent/AU6403600A/en
Publication of WO2000076490A2 publication Critical patent/WO2000076490A2/en
Publication of WO2000076490A3 publication Critical patent/WO2000076490A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for treating urinary frequency and urgency while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer. Pharmaceutical compositions comprising (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer, an antibiotic and a pharmaceutically acceptable carrier are also disclosed.
PCT/US2000/040183 1999-06-10 2000-06-09 Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin WO2000076490A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64036/00A AU6403600A (en) 1999-06-10 2000-06-09 Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32969699A 1999-06-10 1999-06-10
US09/329,696 1999-06-10

Publications (2)

Publication Number Publication Date
WO2000076490A2 WO2000076490A2 (en) 2000-12-21
WO2000076490A3 true WO2000076490A3 (en) 2002-03-21

Family

ID=23286590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040183 WO2000076490A2 (en) 1999-06-10 2000-06-09 Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin

Country Status (2)

Country Link
AU (1) AU6403600A (en)
WO (1) WO2000076490A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273818A (en) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd Percutaneous administration preparation
JPH05339151A (en) * 1992-05-30 1993-12-21 Kodama Kk Sustained release oxybutynin hydrochloride preparation
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
WO1996033678A1 (en) * 1995-04-26 1996-10-31 Theratech, Inc. Triacetin as a transdermal penetration enhancer
WO1996037202A1 (en) * 1995-05-22 1996-11-28 Alza Corporation Dosage form comprising oxybutynin
WO1998000126A1 (en) * 1996-06-28 1998-01-08 Sepracor, Inc. Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin
WO1999024106A1 (en) * 1997-11-06 1999-05-20 Situs Corporation Intravesical infuser
WO1999048494A1 (en) * 1998-03-26 1999-09-30 Alza Corporation Sustained-release composition of oxybutynin with reduced xerostomia effect

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273818A (en) * 1991-02-28 1992-09-30 Kissei Pharmaceut Co Ltd Percutaneous administration preparation
JPH05339151A (en) * 1992-05-30 1993-12-21 Kodama Kk Sustained release oxybutynin hydrochloride preparation
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
WO1996033678A1 (en) * 1995-04-26 1996-10-31 Theratech, Inc. Triacetin as a transdermal penetration enhancer
WO1996037202A1 (en) * 1995-05-22 1996-11-28 Alza Corporation Dosage form comprising oxybutynin
WO1998000126A1 (en) * 1996-06-28 1998-01-08 Sepracor, Inc. Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin
WO1999024106A1 (en) * 1997-11-06 1999-05-20 Situs Corporation Intravesical infuser
WO1999048494A1 (en) * 1998-03-26 1999-09-30 Alza Corporation Sustained-release composition of oxybutynin with reduced xerostomia effect

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199404, Derwent World Patents Index; AN 1994-031722, XP002183937 *
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 *

Also Published As

Publication number Publication date
WO2000076490A2 (en) 2000-12-21
AU6403600A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
CA2211400A1 (en) Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin
CA2257121A1 (en) Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
AU4856097A (en) Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
AU7031500A (en) Therapeutic quinazoline compounds
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
NO20000093L (en) (+) - Norcisapride useful for 5-HT3 and 5-HT4-mediated disorders
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
DE69808440D1 (en) USE OF (+) MEFLOQUINE FOR TREATING MALARIA
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
WO2000076490A3 (en) Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
WO2003002059A3 (en) Tolterodine metabolites
AU4039799A (en) Method for the racemization of optically active amines
BG104416A (en) (1r, 2s,4r)-(-)-2-[(2'-{n,n-dimethylamino}-ethoxy)]-2- [phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane of high purity and its pharmaceutically acceptable with acid salts, method for the preparation of the compounds and medicaments containing one or more of them and their use
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
AU4034699A (en) Method for racemization of optically active amines
WO1999033454A3 (en) S-procyclidine for treating urinary incontinence
WO1996021670A3 (en) Antifungal fusacandins
AU2668201A (en) Method for the production of optically active cyanohydrins using r-oxynitrilase
WO1999033453A3 (en) R-procyclidine for treating urinary incontinence
CA2340920A1 (en) A method for preventing the onset of asthma
CA2358487A1 (en) Use of phanquinone for the treatment or prevention of memory impairment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载